MX2013011266A - Sal de acido benzoico de otamixaban. - Google Patents
Sal de acido benzoico de otamixaban.Info
- Publication number
- MX2013011266A MX2013011266A MX2013011266A MX2013011266A MX2013011266A MX 2013011266 A MX2013011266 A MX 2013011266A MX 2013011266 A MX2013011266 A MX 2013011266A MX 2013011266 A MX2013011266 A MX 2013011266A MX 2013011266 A MX2013011266 A MX 2013011266A
- Authority
- MX
- Mexico
- Prior art keywords
- benzoic acid
- acid salt
- amino
- methyl
- otamixaban
- Prior art date
Links
- 150000001558 benzoic acid derivatives Chemical class 0.000 title abstract 3
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 title abstract 3
- 229950009478 otamixaban Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 108010074860 Factor Xa Proteins 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La invención se relaciona con una sal de ácido benzoico de (2R, 3R)-2-{3-[amino(imino)metil]bencil}-3-{[4-(1-oxidopiridin-4-iI)be nzoil]amino}butanoato de metilo, y con una sal de ácido benzoico de (2R,3R)-2-{3-[amino(imino)metil]bencil}-3-{[4-(1-oxidopiridin-4 -il)benzoil]amino)butanoato de metilo que está en una forma cristalina o en por lo menos una forma parcialmente cristalina, así como con los procesos para su preparación, con los métodos para usar tal sal para tratar a los sujetos que sufren de condiciones que se pueden aliviar por la administración de un inhibidor del factor Xa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305348 | 2011-03-29 | ||
| US201161500342P | 2011-06-23 | 2011-06-23 | |
| PCT/EP2012/055364 WO2012130821A1 (en) | 2011-03-29 | 2012-03-27 | Benzoic acid salt of otamixaban |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013011266A true MX2013011266A (es) | 2014-03-27 |
Family
ID=44065390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013011266A MX2013011266A (es) | 2011-03-29 | 2012-03-27 | Sal de acido benzoico de otamixaban. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8993602B2 (es) |
| EP (1) | EP2691371B1 (es) |
| JP (1) | JP5959617B2 (es) |
| KR (1) | KR101852226B1 (es) |
| CN (1) | CN103562183B (es) |
| AU (1) | AU2012234325B2 (es) |
| BR (1) | BR112013025105A2 (es) |
| CA (1) | CA2830965C (es) |
| CY (1) | CY1116659T1 (es) |
| DK (1) | DK2691371T3 (es) |
| ES (1) | ES2539236T3 (es) |
| HR (1) | HRP20150613T1 (es) |
| IL (1) | IL228574A (es) |
| MX (1) | MX2013011266A (es) |
| MY (1) | MY161396A (es) |
| PL (1) | PL2691371T3 (es) |
| PT (1) | PT2691371E (es) |
| RU (1) | RU2597423C2 (es) |
| SG (1) | SG193612A1 (es) |
| SI (1) | SI2691371T1 (es) |
| WO (1) | WO2012130821A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012130819A1 (en) | 2011-03-29 | 2012-10-04 | Sanofi | Otamixaban formulations with improved stability |
| CN106565698B (zh) * | 2016-08-15 | 2019-03-08 | 南京帕隆材料科技有限公司 | 取代噻唑类衍生物及其制备方法和用途 |
| CN106518859B (zh) * | 2016-08-15 | 2019-01-18 | 南京帕隆材料科技有限公司 | 噻唑类衍生物及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424334A (en) | 1991-12-19 | 1995-06-13 | G. D. Searle & Co. | Peptide mimetic compounds useful as platelet aggregation inhibitors |
| US6080767A (en) * | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| CA2241904C (en) * | 1996-01-02 | 2004-12-21 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| GB0108903D0 (en) * | 2000-10-05 | 2001-05-30 | Aventis Pharm Prod Inc | Novel crystalline forms of a factor Xa inhibitor |
| KR101509829B1 (ko) * | 2007-05-02 | 2015-04-06 | 포톨라 파마슈티컬스, 인코포레이티드 | 혈소판 ａｄｐ 수용체 억제제로 작용하는 화합물을 이용한 병용요법 |
| SG177772A1 (en) * | 2009-07-29 | 2012-03-29 | Sanofi Sa | Otamixaban for treatment of elderly and renal impaired non-st elevation myocardial infarction patients |
-
2012
- 2012-03-27 SI SI201230219T patent/SI2691371T1/sl unknown
- 2012-03-27 MX MX2013011266A patent/MX2013011266A/es active IP Right Grant
- 2012-03-27 EP EP12711858.6A patent/EP2691371B1/en active Active
- 2012-03-27 MY MYPI2013003459A patent/MY161396A/en unknown
- 2012-03-27 BR BR112013025105A patent/BR112013025105A2/pt not_active Application Discontinuation
- 2012-03-27 CA CA2830965A patent/CA2830965C/en not_active Expired - Fee Related
- 2012-03-27 KR KR1020137028416A patent/KR101852226B1/ko not_active Expired - Fee Related
- 2012-03-27 PT PT127118586T patent/PT2691371E/pt unknown
- 2012-03-27 PL PL12711858T patent/PL2691371T3/pl unknown
- 2012-03-27 CN CN201280026534.0A patent/CN103562183B/zh active Active
- 2012-03-27 RU RU2013148005/04A patent/RU2597423C2/ru not_active IP Right Cessation
- 2012-03-27 WO PCT/EP2012/055364 patent/WO2012130821A1/en not_active Ceased
- 2012-03-27 HR HRP20150613TT patent/HRP20150613T1/hr unknown
- 2012-03-27 DK DK12711858.6T patent/DK2691371T3/da active
- 2012-03-27 ES ES12711858.6T patent/ES2539236T3/es active Active
- 2012-03-27 SG SG2013071766A patent/SG193612A1/en unknown
- 2012-03-27 JP JP2014501569A patent/JP5959617B2/ja active Active
- 2012-03-27 AU AU2012234325A patent/AU2012234325B2/en not_active Ceased
- 2012-03-27 US US14/008,332 patent/US8993602B2/en active Active
-
2013
- 2013-09-29 IL IL228574A patent/IL228574A/en active IP Right Grant
-
2015
- 2015-06-17 CY CY20151100521T patent/CY1116659T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140024684A1 (en) | 2014-01-23 |
| KR20140022851A (ko) | 2014-02-25 |
| CA2830965C (en) | 2019-04-09 |
| SG193612A1 (en) | 2013-11-29 |
| MY161396A (en) | 2017-04-14 |
| BR112013025105A2 (pt) | 2017-06-06 |
| AU2012234325A1 (en) | 2013-10-17 |
| EP2691371B1 (en) | 2015-03-18 |
| IL228574A (en) | 2015-07-30 |
| RU2597423C2 (ru) | 2016-09-10 |
| CN103562183B (zh) | 2015-12-23 |
| CY1116659T1 (el) | 2017-03-15 |
| JP5959617B2 (ja) | 2016-08-02 |
| KR101852226B1 (ko) | 2018-04-25 |
| PL2691371T3 (pl) | 2015-08-31 |
| RU2013148005A (ru) | 2015-05-10 |
| JP2014509622A (ja) | 2014-04-21 |
| HK1189584A1 (en) | 2014-06-13 |
| CA2830965A1 (en) | 2012-10-04 |
| DK2691371T3 (da) | 2015-06-22 |
| ES2539236T3 (es) | 2015-06-29 |
| PT2691371E (pt) | 2015-07-20 |
| SI2691371T1 (sl) | 2015-07-31 |
| WO2012130821A1 (en) | 2012-10-04 |
| US8993602B2 (en) | 2015-03-31 |
| HRP20150613T1 (hr) | 2015-07-17 |
| EP2691371A1 (en) | 2014-02-05 |
| IL228574A0 (en) | 2013-12-31 |
| AU2012234325B2 (en) | 2016-08-11 |
| CN103562183A (zh) | 2014-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014028589A3 (en) | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| IN2015DN02573A (es) | ||
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| EA201390917A1 (ru) | Дигетероарильные соединения в качестве ингибиторов vps34 | |
| NZ704662A (en) | Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid | |
| IN2014KN00948A (es) | ||
| EA201390934A1 (ru) | Композиции и способы модулирования fxr | |
| MX2013005533A (es) | Derivados de acido amino-bisfenil-pentanoico sustituidos como inhibidores de nep. | |
| PH12013500411A1 (en) | Treatment of myocardial infarction using tgf - beta antagonists | |
| PH12014502567A1 (en) | Piperidine derivatives for gpr119 agonist | |
| EA201490928A1 (ru) | Способы лечения острых приступов подагры | |
| PH12013502530A1 (en) | Glioblastoma inhibiting compounds and their use | |
| PH12013501991A1 (en) | Otamixaban formulations with improved stability | |
| PH12013500545A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| BR112012020629A2 (pt) | forma cristalina, e, método para a terapia de um distúrbio | |
| MY164880A (en) | Process for the preparation of isoxazolyl-methoxy-nicotinic acids | |
| MX2013011266A (es) | Sal de acido benzoico de otamixaban. | |
| WO2013117503A3 (en) | Pi3k inhibitors for treating fibrotic diseases | |
| EA201391586A1 (ru) | ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ | |
| WO2012148148A3 (en) | Novel zinc azide complex and a process for preparing tetrazole derivatives using the same | |
| WO2010065069A3 (en) | Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders | |
| MX2015010434A (es) | Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo. | |
| MY162945A (en) | Azole derivative | |
| MX351994B (es) | Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico. | |
| WO2013054364A3 (en) | Novel salts of sitagliptin, process for the preparation and pharmaceutical composition thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |